It is well suited for use across a wide range of occupied, commercial areas such as entertainment venues, including lobbies, auditoriums, and restrooms, as well as other indoor spaces. Mass production of the new Christie CounterAct fixture starts in January 2021.ĭeveloped by Christie’s parent company, Ushio Inc., using IP licensed from Columbia University based on research by Columbia University's Center for Radiological Research, the revolutionary Care222 far-UVC, mercury-free excimer lamp-highlighted in FORTUNE magazine’s annual Change the World list 1 in 2020, includes a proprietary short pass filter that prevents the emission of longer wavelengths of UV light (230nm and higher) that are capable of penetrating human skin and eyes, an especially important feature that other 222nm and far-UVC products do not have.Ĭhristie CounterAct introduces an added layer of defense against pathogens in indoor venues when guests and staff are presentĬhristie CounterAct is a line of fixtures that are simple to control remotely and can be installed on ceilings as easily as a commercial lighting fixture. Unlike comparable products, the Christie fixture uses Ushio’s patented narrowband filtered Care222 excimer lamps that emit far-UVC 222nm light - the only UV technology shown to continuously and significantly reduce pathogens, like coronaviruses, that may also be used while people are present, when used in accordance with specified parameters. CYPRESS, Calif – Christie ® is pleased to announce the launch of the Christie ® CounterAct ™ line of commercial UV disinfection products with patented Care222 ® far-UVC light technology for cinemas, theme parks, museums, sports complexes and other indoor spaces.
0 Comments
Leave a Reply. |